Pieris Pharmaceuticals Inc (PIRS)

[Seel]

This is big news everyone, even though its still preclinical.

http://www.pieris.com/news-and-events/press-releases/detail/543/pieris-pharmaceuticals-presents-positive-data-for-its-lead
PIERIS PHARMACEUTICALS PRESENTS POSITIVE DATA FOR ITS LEAD BISPECIFIC DRUG CANDIDATE, PRS-343, AT THE 2016 CRI-CIMT-EATI-AACR INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE

Download PDF
NOVEL 4-1BB/HER2 BISPECIFIC DEMONSTRATES DIFFERENTIATION OVER CONVENTIONAL 4-1BB MAB AND HER2 MAB APPROACHES

BOSTON, MA -- (Marketwired) -- 09/26/16 -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform, announced that it has today presented new preclinical data demonstrating in vivo efficacy of its lead 4-1BB (CD137)-based bispecific cancer immunotherapeutic drug candidate, PRS-343, at the 2016 CRI-CIMT-AACR International Cancer Immunotherapy Conference - Translating Science into Survival, taking place in New York City.

The in vivo data show that treatment of HER2-positive tumor-bearing animals with PRS-343 provided dose-dependent, dual anti-tumor activity by increasing the frequency of tumor-infiltrating lymphocytes via bispecific targeting of 4-1BB and HER2, as well as mediating tumor growth inhibition by direct antagonism of HER2 on tumor cells. In contrast, an agonistic anti-4-1BB benchmark monoclonal antibody (mAb) displayed neither tumor growth inhibition nor enhanced lymphocyte infiltration into tumors compared to an isotype control mAb, but preferentially activated T cells systemically, resulting in significant toxicity. A copy of the poster can be viewed and downloaded by clicking http://www.pieris.com/pirs-cri-poster-2016.